🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Use of a New Diagnostic Tool in the Detection and Characterization of Endometriosis Lesions

RecruitingNAAges 18 Years - anyFemaleUniversity Hospital, Toulouse
NCT07053982 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Diagnostic wandering is one of the characteristics of endometriosis due to great anatomical and clinical variability but also due to poorly relevant diagnostic examinations. \[18F\]-FES PET/CT could on the one hand improve diagnosis by showing greater sensitivity than MRI and on the other hand make it possible to quantify and characterize the expression of ER from diagnosis and thus helping to guide therapeutic care. We will thus attempt to correlate the intensity of \[18F\]-FES PET/CT with the expression of estrogen receptors and the intensity of pain.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: Cases: \- Painful patients with a VAS ≥ 4 treated surgically for painful symptoms related to endometriosis; Controls: * Patient with a VAS \< 4 treated surgically for endometriosis in the context of infertility; * Age \> 18 years; * Patient who provided informed consent; * Patients who underwent a preoperative MRI and were not contraindicated for \[18F\]-FES PET/CT; * Patient who underwent surgery mid-cycle; * Affiliation to a social security scheme Exclusion Criteria: * Patient treated for endometriosis without surgery; * Pregnant patient * Patient taking hormone therapy * Menopausal patient * Hypersensitivity to the active substance (Fluoroestradiol (18F)) or to any of the excipients * Patient under legal protection * Claustrophobic patient
💊

What it tests

  • Preoperative [18F]-FES PET/CT Imaging and Estrogen Receptor Expression Analysis in Endometriosis Surgery
📍

Where

1 site
Toulouse, Rangueil Hospital
Toulouse, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy